JP7100227B2 - 疾患の治療のための化合物、組成物、および方法 - Google Patents

疾患の治療のための化合物、組成物、および方法 Download PDF

Info

Publication number
JP7100227B2
JP7100227B2 JP2019520928A JP2019520928A JP7100227B2 JP 7100227 B2 JP7100227 B2 JP 7100227B2 JP 2019520928 A JP2019520928 A JP 2019520928A JP 2019520928 A JP2019520928 A JP 2019520928A JP 7100227 B2 JP7100227 B2 JP 7100227B2
Authority
JP
Japan
Prior art keywords
alkyl
aryl
heteroaryl
compound
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019520928A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019532084A5 (enExample
JP2019532084A (ja
Inventor
アイヤー，ラーダークリシュナン・ピー
シェリ，アンジャーネユル
パドマナブハン，シータラマイヤー
メヘル，ギータ
ジョウ，シュヨンホワ
チャラ，スリーロッパ
ギミ，レイオマンド・エイチ
クリアリー，ディロン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F-Star Therapeutics Ltd
Original Assignee
F-Star Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F-Star Therapeutics Ltd filed Critical F-Star Therapeutics Ltd
Publication of JP2019532084A publication Critical patent/JP2019532084A/ja
Publication of JP2019532084A5 publication Critical patent/JP2019532084A5/ja
Priority to JP2022078657A priority Critical patent/JP2022106989A/ja
Application granted granted Critical
Publication of JP7100227B2 publication Critical patent/JP7100227B2/ja
Priority to JP2023162456A priority patent/JP7749629B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2019520928A 2016-07-06 2017-07-06 疾患の治療のための化合物、組成物、および方法 Active JP7100227B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022078657A JP2022106989A (ja) 2016-07-06 2022-05-12 疾患の治療のための化合物、組成物、および方法
JP2023162456A JP7749629B2 (ja) 2016-07-06 2023-09-26 疾患の治療のための化合物、組成物、および方法

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US201662359039P 2016-07-06 2016-07-06
US62/359,039 2016-07-06
US201662363118P 2016-07-15 2016-07-15
US62/363,118 2016-07-15
US201662403530P 2016-10-03 2016-10-03
US62/403,530 2016-10-03
US201662411424P 2016-10-21 2016-10-21
US62/411,424 2016-10-21
US201762444141P 2017-01-09 2017-01-09
US62/444,141 2017-01-09
US201762462679P 2017-02-23 2017-02-23
US62/462,679 2017-02-23
US201762470746P 2017-03-13 2017-03-13
US62/470,746 2017-03-13
US201762508846P 2017-05-19 2017-05-19
US62/508,846 2017-05-19
PCT/US2017/040882 WO2018009648A1 (en) 2016-07-06 2017-07-06 Compounds, compositions, and methods for the treatment of disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022078657A Division JP2022106989A (ja) 2016-07-06 2022-05-12 疾患の治療のための化合物、組成物、および方法

Publications (3)

Publication Number Publication Date
JP2019532084A JP2019532084A (ja) 2019-11-07
JP2019532084A5 JP2019532084A5 (enExample) 2020-08-06
JP7100227B2 true JP7100227B2 (ja) 2022-07-13

Family

ID=60913147

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019520928A Active JP7100227B2 (ja) 2016-07-06 2017-07-06 疾患の治療のための化合物、組成物、および方法
JP2022078657A Pending JP2022106989A (ja) 2016-07-06 2022-05-12 疾患の治療のための化合物、組成物、および方法
JP2023162456A Active JP7749629B2 (ja) 2016-07-06 2023-09-26 疾患の治療のための化合物、組成物、および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022078657A Pending JP2022106989A (ja) 2016-07-06 2022-05-12 疾患の治療のための化合物、組成物、および方法
JP2023162456A Active JP7749629B2 (ja) 2016-07-06 2023-09-26 疾患の治療のための化合物、組成物、および方法

Country Status (13)

Country Link
US (2) US11033569B2 (enExample)
EP (1) EP3481402A4 (enExample)
JP (3) JP7100227B2 (enExample)
KR (1) KR102569881B1 (enExample)
CN (1) CN109843302B (enExample)
AU (1) AU2017293781B2 (enExample)
CA (1) CA3029644A1 (enExample)
IL (1) IL264049B2 (enExample)
MX (2) MX392605B (enExample)
MY (1) MY199689A (enExample)
SG (1) SG11201811709WA (enExample)
TW (1) TWI689514B (enExample)
WO (1) WO2018009648A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022106989A (ja) * 2016-07-06 2022-07-20 エフ－スター・セラピューティクス・インコーポレイテッド 疾患の治療のための化合物、組成物、および方法

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL280430B2 (en) 2016-03-18 2023-11-01 Univ Texas Cyclic dinucleotide compounds and methods of use
WO2018100558A2 (en) 2016-12-01 2018-06-07 Takeda Pharmaceutical Company Limited Cyclic dinucleotide
JP7160833B2 (ja) 2017-04-13 2022-10-25 サイロパ ビー．ブイ． 抗ｓｉｒｐアルファ抗体
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
PH12020550585A1 (en) 2017-11-10 2021-04-19 Takeda Pharmaceuticals Co Sting modulator compounds, and methods of making and using
JP7037667B2 (ja) 2017-12-20 2022-03-16 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する３’３’環状ジヌクレオチド
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
WO2020014127A1 (en) * 2018-07-10 2020-01-16 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
TW202030199A (zh) * 2018-07-17 2020-08-16 美商健生生物科技公司 作為ｓｔｉｎｇ促效劑之環狀二核苷酸
CN118846110A (zh) 2018-09-06 2024-10-29 第一三共株式会社 抗体药物偶联物
MA53659A (fr) 2018-09-21 2022-02-23 Shanghai De Novo Pharmatech Co Ltd Analogue dinucléotidique cyclique, composition pharmaceutique associée et utilisation
EP3873484B1 (en) 2018-10-29 2023-08-23 Venenum Biodesign, LLC Novel sting agonists
US11110106B2 (en) 2018-10-29 2021-09-07 Venenum Biodesign, LLC Sting agonists for treating bladder cancer and solid tumors
CN113348181A (zh) 2018-10-31 2021-09-03 诺华股份有限公司 包含sting激动剂的dc-sign抗体缀合物
US12257265B2 (en) 2019-01-10 2025-03-25 Shenzhen Ying Biopharmaceutical Co., Ltd Cyclic dinucleotide prodrug molecule, preparation method therefor and application thereof
CN113574063B (zh) * 2019-03-07 2025-03-18 捷克共和国有机化学与生物化学研究所 3’3’-环二核苷酸及其前药
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
WO2020178769A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
CN114127082A (zh) 2019-05-09 2022-03-01 阿里戈斯治疗公司 作为sting调节剂的经修饰的环状二核苷化合物
WO2021007160A1 (en) 2019-07-05 2021-01-14 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
US12678512B2 (en) 2020-03-06 2026-07-14 Daiichi Sankyo Company, Limited Anti-EGFR antibody-drug conjugate with a cyclic dinucleotide derivative
US20230141284A1 (en) 2020-04-10 2023-05-11 Ono Pharmaceutical Co., Ltd. Cancer therapeutic method
CN111909223A (zh) * 2020-07-17 2020-11-10 清华大学 环二核苷酸共价修饰物及其制备方法和应用
JP2023537066A (ja) 2020-08-07 2023-08-30 タンボ・インコーポレイテッド トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用
EP4209506A4 (en) 2020-09-02 2024-10-09 Daiichi Sankyo Company, Limited NEW ENDO-N-ACETYL GLUCOSAMINIDASE
JP7397996B2 (ja) 2020-11-09 2023-12-13 武田薬品工業株式会社 抗体薬物コンジュゲート
IL315341A (en) 2022-03-02 2024-10-01 Daiichi Sankyo Co Ltd METHOD FOR PRODUCING Fc-CONTAINING MOLECULE
KR20250054799A (ko) 2022-08-29 2025-04-23 다이이찌 산쿄 가부시키가이샤 변이 Fc 영역을 포함하는 항체 약물 콘쥬게이트
WO2024076728A1 (en) * 2022-10-06 2024-04-11 Dana-Farber Cancer Institute, Inc. Cyclic nucleotides and uses thereof
DE212025000115U1 (de) 2024-07-30 2026-06-18 Sairopa B.V. Anti-SIRP Alpha-Antikörperformulierungen und ihre Verwendung

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007529531A (ja) 2004-03-15 2007-10-25 ケイ．アール． カラオリス，デイヴィッド 免疫、炎症または神経保護応答のための方法
CN102199183A (zh) 2010-03-26 2011-09-28 北京大学 环二鸟苷酸及其类似物和制备方法
US20120178710A1 (en) 2009-07-01 2012-07-12 Rutgers, The State University Of New Jersey Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof
WO2014189805A1 (en) 2013-05-18 2014-11-27 Auro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
WO2015185565A1 (en) 2014-06-04 2015-12-10 Glaxosmithkline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of sting
JP2016503029A (ja) 2012-12-13 2016-02-01 アデュロ バイオテック，インコーポレイテッド 明確な立体化学を有する環状プリンジヌクレオチドを含む組成物ならびにそれらの調製および使用方法
WO2016096174A1 (en) 2014-12-16 2016-06-23 Invivogen Fluorinated cyclic dinucleotides for cytokine induction

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2257704B (en) * 1991-07-18 1995-03-01 Erba Carlo Spa Cyclic oligonucleotides phosphorothioates
JP4874801B2 (ja) * 2003-06-11 2012-02-15 イデラ ファーマシューティカルズ インコーポレイテッド 安定化免疫調節オリゴヌクレオチド
US7592326B2 (en) * 2004-03-15 2009-09-22 Karaolis David K R Method for stimulating the immune, inflammatory or neuroprotective response
EP2858722B8 (en) 2012-06-08 2018-02-21 Aduro BioTech, Inc. Compostions and methods for cancer immunotherapy
JP2016506408A (ja) * 2012-12-19 2016-03-03 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 哺乳動物の環状ジヌクレオチドシグナル伝達経路の薬学的標的化
JP6243443B2 (ja) * 2012-12-20 2017-12-06 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 全身健康状態の尺度としてのパターン認識受容体の発現
WO2014109256A1 (ja) * 2013-01-09 2014-07-17 国立大学法人東北大学 トリアゾール連結型環状ジヌクレオチド類縁体
CA2840937A1 (en) * 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for transdermal administration
CN105377867B (zh) * 2013-05-03 2019-11-12 加利福尼亚大学董事会 I型干扰素的环状二核苷酸诱导
CN103864910B (zh) * 2014-03-03 2016-01-20 中国科学院南海海洋研究所 一种新型特异结合lps的贝类模式识别受体lrrp
KR20200029627A (ko) 2014-03-12 2020-03-18 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
EP3233191A1 (en) 2014-12-16 2017-10-25 Invivogen Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
TWI706958B (zh) * 2015-03-10 2020-10-11 美商艾杜諾生物科技公司 活化「干擾素基因刺激因子」依賴性訊息傳導之組合物及方法
CN108137641B (zh) 2015-08-13 2022-04-01 默沙东公司 作为sting激动剂的环状双核苷酸化合物
KR20180066241A (ko) 2015-10-28 2018-06-18 아두로 바이오테크, 인코포레이티드 “인터페론 유전자의 자극제”-의존성 신호전달을 활성화시키기 위한 조성물 및 방법
JP6411676B2 (ja) * 2015-12-03 2018-10-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｓｔｉｎｇの調節因子としての環状プリンジヌクレオチド
CN106540260A (zh) 2015-12-09 2017-03-29 聊城市奥润生物医药科技有限公司 干扰素基因刺激蛋白（sting）激动剂在抗阿尔兹海默症中的应用
US20180369268A1 (en) * 2015-12-16 2018-12-27 Aduro Biotech, Inc. Methods for identifying inhibitors of "stimulator of interferon gene"- dependent interferon production
WO2017123657A1 (en) 2016-01-11 2017-07-20 Gary Glick Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
SMT202500412T1 (it) 2016-01-11 2025-11-10 Innate Tumor Immunity Inc Dinucleotidi ciclici per il trattamento di condizioni associate all’attività di sting quali il cancro
CN109069440A (zh) 2016-03-02 2018-12-21 得克萨斯州大学系统董事会 用于免疫治疗的激活sting的纳米疫苗
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
CA3029644A1 (en) * 2016-07-06 2018-01-11 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
US20190345191A1 (en) 2016-08-31 2019-11-14 Innate Tumor Immunity, Inc. Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity
JP6636673B2 (ja) 2016-10-04 2020-01-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ＳＴＩＮＧアゴニストとしてのベンゾ［ｂ］チオフェン化合物
WO2018100558A2 (en) 2016-12-01 2018-06-07 Takeda Pharmaceutical Company Limited Cyclic dinucleotide
RU2019122598A (ru) 2016-12-20 2021-01-22 Мерк Шарп И Доум Корп. Циклические динуклеотидные агонисты sting для лечения рака
WO2018118664A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
CA3053568A1 (en) 2017-02-21 2018-08-30 Board Of Regents, The University Of Texas System Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US11466047B2 (en) 2017-05-12 2022-10-11 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
JP2020524718A (ja) 2017-06-22 2020-08-20 キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ ヒトｓｔｉｎｇの複素環式小分子調節因子
CN111132972B (zh) 2017-06-22 2024-07-12 克拉德夫制药有限公司 人sting的小分子调节剂
US20200138827A1 (en) 2017-06-22 2020-05-07 Curadev Pharma Limited Small molecule modulators of human sting
US11707531B2 (en) * 2017-09-11 2023-07-25 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007529531A (ja) 2004-03-15 2007-10-25 ケイ．アール． カラオリス，デイヴィッド 免疫、炎症または神経保護応答のための方法
US20120178710A1 (en) 2009-07-01 2012-07-12 Rutgers, The State University Of New Jersey Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof
CN102199183A (zh) 2010-03-26 2011-09-28 北京大学 环二鸟苷酸及其类似物和制备方法
JP2016503029A (ja) 2012-12-13 2016-02-01 アデュロ バイオテック，インコーポレイテッド 明確な立体化学を有する環状プリンジヌクレオチドを含む組成物ならびにそれらの調製および使用方法
WO2014189805A1 (en) 2013-05-18 2014-11-27 Auro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
WO2015185565A1 (en) 2014-06-04 2015-12-10 Glaxosmithkline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of sting
WO2016096174A1 (en) 2014-12-16 2016-06-23 Invivogen Fluorinated cyclic dinucleotides for cytokine induction

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HSU,C.Y. et al，RNA polymerase: linear competitive inhibition by bis-(3'→5')-cyclic dinucleotides, cyclic NpNp，Nucleic Acids Research，1982年，Vol.10, No.18，pp.5637-5647
MICURA,R.，Cyclic oligoribonucleotides (RNA) by solid-phase synthesis，Chemistry - A European Journal，1999年，Vol.5, No.7，pp.2077-2082

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022106989A (ja) * 2016-07-06 2022-07-20 エフ－スター・セラピューティクス・インコーポレイテッド 疾患の治療のための化合物、組成物、および方法
JP2023182645A (ja) * 2016-07-06 2023-12-26 エフ－スター・セラピューティクス・インコーポレイテッド 疾患の治療のための化合物、組成物、および方法
JP7749629B2 (ja) 2016-07-06 2025-10-06 インボックス ファーマ リミテッド 疾患の治療のための化合物、組成物、および方法

Also Published As

Publication number Publication date
TW201805295A (zh) 2018-02-16
KR20190032408A (ko) 2019-03-27
MX2022006260A (es) 2022-06-29
KR102569881B1 (ko) 2023-08-22
TWI689514B (zh) 2020-04-01
WO2018009648A1 (en) 2018-01-11
IL264049B1 (en) 2023-07-01
US11033569B2 (en) 2021-06-15
NZ750055A (en) 2025-08-29
US20190262372A1 (en) 2019-08-29
MY199689A (en) 2023-11-17
SG11201811709WA (en) 2019-01-30
JP2022106989A (ja) 2022-07-20
JP2023182645A (ja) 2023-12-26
CN109843302B (zh) 2022-11-29
AU2017293781B2 (en) 2022-12-22
EP3481402A4 (en) 2020-01-22
US11744845B2 (en) 2023-09-05
EP3481402A1 (en) 2019-05-15
AU2017293781A1 (en) 2019-02-07
CN109843302A (zh) 2019-06-04
MX392605B (es) 2025-03-11
MX2019000216A (es) 2019-11-12
JP7749629B2 (ja) 2025-10-06
IL264049A (en) 2019-01-31
CA3029644A1 (en) 2018-01-11
IL264049B2 (en) 2023-11-01
US20220054523A1 (en) 2022-02-24
JP2019532084A (ja) 2019-11-07

Similar Documents

Publication Publication Date Title
JP7749629B2 (ja) 疾患の治療のための化合物、組成物、および方法
TWI688390B (zh) 化合物、組合物及用於治療疾病之方法
US12390668B2 (en) Compounds, compositions, and methods for the treatment of disease
JP2019521138A (ja) 疾患の治療のための化合物、組成物、および方法
US11584774B2 (en) Compounds, compositions, and methods for the treatment of disease
WO2019161171A1 (en) Nanoparticle formulations of sting agonists
US12291548B2 (en) Compounds, compositions, and methods for the treatment of disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200626

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210713

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220113

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220315

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220411

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220511

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220616

R150 Certificate of patent or registration of utility model

Ref document number: 7100227

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250